Free Trial
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

BioXcel Therapeutics logo
$1.37 +0.06 (+4.58%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.01 (+0.73%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

Key Stats

Today's Range
$1.33
$2.07
50-Day Range
$1.18
$2.05
52-Week Range
$1.17
$16.72
Volume
109.14 million shs
Average Volume
340,166 shs
Market Capitalization
$8.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.60
Consensus Rating
Moderate Buy

Company Overview

BioXcel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

BTAI MarketRank™: 

BioXcel Therapeutics scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioXcel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    BioXcel Therapeutics has received no research coverage in the past 90 days.

  • Read more about BioXcel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($24.39) to ($16.32) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioXcel Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioXcel Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BioXcel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.37% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently increased by 4.70%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    BioXcel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BioXcel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.37% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently increased by 4.70%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BioXcel Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    11 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.20% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.68% of the stock of BioXcel Therapeutics is held by institutions.

  • Read more about BioXcel Therapeutics' insider trading history.
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

Digital Dollar Alert: Protect Your Wealth Before It’s Too Late
134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.
See More Headlines

BTAI Stock Analysis - Frequently Asked Questions

BioXcel Therapeutics' stock was trading at $5.9824 at the start of the year. Since then, BTAI stock has decreased by 77.1% and is now trading at $1.37.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its quarterly earnings data on Monday, May, 12th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.72) by $1.22. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.35 million.

BioXcel Therapeutics shares reverse split before market open on Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

BioXcel Therapeutics (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA).

Company Calendar

Last Earnings
5/12/2025
Today
8/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BTAI
CIK
1720893
Fax
N/A
Employees
90
Year Founded
2017

Price Target and Rating

High Price Target
$80.00
Low Price Target
$4.00
Potential Upside/Downside
+3,009.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.60 million
Net Margins
-2,163.18%
Pretax Margin
-2,163.18%
Return on Equity
N/A
Return on Assets
-83.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.48
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$2.27 million
Price / Sales
3.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($30.01) per share
Price / Book
-0.05

Miscellaneous

Outstanding Shares
6,060,000
Free Float
4,772,000
Market Cap
$8.30 million
Optionable
Optionable
Beta
0.05

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:BTAI) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners